Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
28 Sep 2020
Historique:
received: 17 08 2020
revised: 25 09 2020
accepted: 25 09 2020
entrez: 1 10 2020
pubmed: 2 10 2020
medline: 20 3 2021
Statut: epublish

Résumé

Albumin binding domain-Derived Affinity ProTeins (ADAPTs) are small (5 kDa) engineered scaffold proteins that are promising targeting agents for radionuclide-based imaging. A recent clinical study has demonstrated that radiolabeled ADAPTs can efficiently visualize human epidermal growth factor receptor 2 (HER2) expression in breast cancer using SPECT imaging. However, the use of ADAPTs directly labeled with radiometals for targeted radionuclide therapy is limited by their high reabsorption and prolonged retention of activity in kidneys. In this study, we investigated whether a co-injection of lysine or gelofusin, commonly used for reduction of renal uptake of radiolabeled peptides in clinics, would reduce the renal uptake of [

Identifiants

pubmed: 32998229
pii: molecules25194448
doi: 10.3390/molecules25194448
pmc: PMC7583817
pii:
doi:

Substances chimiques

Proteins 0
Radiopharmaceuticals 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : 075-15-2019-1925

Références

J Nucl Med. 2012 Jun;53(6):953-60
pubmed: 22586147
Lab Invest. 1982 Jan;46(1):79-88
pubmed: 7054592
J Biol Chem. 1980 Sep 10;255(17):8239-44
pubmed: 6773936
Mol Cancer Ther. 2009 Oct;8(10):2861-71
pubmed: 19825804
J Nucl Med. 2010 Jul;51(7):1049-58
pubmed: 20554737
Molecules. 2020 Jun 09;25(11):
pubmed: 32526905
Curr Opin Chem Eng. 2013 Nov;2(4):
pubmed: 24358455
J Nucl Med. 2018 Jul;59(7):1092-1098
pubmed: 29439013
Contrast Media Mol Imaging. 2011 Mar-Apr;6(2):85-92
pubmed: 20936711
Cancer Res. 2007 Mar 15;67(6):2773-82
pubmed: 17363599
Eur J Nucl Med. 1998 Feb;25(2):201-12
pubmed: 9473271
J Crit Care. 2001 Sep;16(3):115-20
pubmed: 11689768
Theranostics. 2016 Jan 01;6(1):93-103
pubmed: 26722376
PLoS One. 2014 Aug 04;9(8):e103094
pubmed: 25089830
Eur J Pharm Biopharm. 2019 Jul;140:109-120
pubmed: 31082509
Cancer Res. 2015 Oct 15;75(20):4364-71
pubmed: 26297736
Amino Acids. 2011 Nov;41(5):1037-47
pubmed: 20174842
Am J Physiol. 1989 Aug;257(2 Pt 1):C397-407
pubmed: 2669509
Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):2129-34
pubmed: 17694308
Comput Struct Biotechnol J. 2013 Sep 01;6:e201303009
pubmed: 24688717
J Nucl Med. 2005 Oct;46(10):1696-700
pubmed: 16204720
J Nucl Med. 2007 Apr;48(4):596-601
pubmed: 17401097
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):288-301
pubmed: 25391547
Sci Rep. 2017 Nov 7;7(1):14780
pubmed: 29116215
Nat Rev Mol Cell Biol. 2002 Apr;3(4):256-66
pubmed: 11994745
Mol Pharm. 2018 Jul 2;15(7):2674-2683
pubmed: 29865791
Expert Rev Proteomics. 2014 Oct;11(5):561-72
pubmed: 25163524
Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1136-43
pubmed: 15912401
J Nucl Med. 2020 Aug 17;:
pubmed: 32817142
Curr Probl Clin Biochem. 1977 Oct 23-26;8:406-15
pubmed: 28903
Eur J Pharm Biopharm. 2019 Jan;134:37-48
pubmed: 30408518
J Nucl Med. 2018 Jan;59(1):93-99
pubmed: 28864631
Contrast Media Mol Imaging. 2018 Jun 6;2018:6930425
pubmed: 29977173
Theranostics. 2016 Jan 01;6(2):262-71
pubmed: 26877784
J Nucl Med. 1996 Aug;37(8):1388-92
pubmed: 8708781
Int J Biol Macromol. 2020 Feb 15;145:216-225
pubmed: 31863835
J Nucl Med. 2004 Apr;45(4):709-13
pubmed: 15073269
Update Cancer Ther. 2007 Mar;2(1):19-31
pubmed: 18311322
Mol Pharm. 2019 Mar 4;16(3):995-1008
pubmed: 30608701
J Nucl Med. 2014 May;55(5):730-5
pubmed: 24665085
Bioconjug Chem. 2016 Mar 16;27(3):716-26
pubmed: 26781756
Pediatr Nephrol. 2002 Dec;17(12):993-9
pubmed: 12478347
Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):692-701
pubmed: 19066886
J Nucl Med. 2018 Jun;59(6):885-891
pubmed: 29545374
Curr Hypertens Rep. 2020 Mar 14;22(4):30
pubmed: 32172431
Cancer Biother Radiopharm. 2013 Apr;28(3):187-95
pubmed: 23461385
Ren Physiol. 1985;8(1):8-18
pubmed: 3969509
Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):623-32
pubmed: 21170526
EJNMMI Res. 2020 Feb 4;10(1):7
pubmed: 32020413
Sci Rep. 2019 Jun 28;9(1):9405
pubmed: 31253840

Auteurs

Anzhelika Vorobyeva (A)

Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, National Research Tomsk Polytechnic University, 634 050 Tomsk, Russia.

Maryam Oroujeni (M)

Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.

Sarah Lindbo (S)

Department of Protein Technology, KTH-Royal Institute of Technology, 10691 Stockholm, Sweden.

Sophia Hober (S)

Department of Protein Technology, KTH-Royal Institute of Technology, 10691 Stockholm, Sweden.

Tianqi Xu (T)

Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.

Yongsheng Liu (Y)

Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.

Sara S Rinne (SS)

Department of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden.

Javad Garousi (J)

Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH